No description available.

Ribonuclease III is a highly-conserved bacterial enzyme that cleaves double-stranded (ds) RNA structures, and participates in diverse RNA maturation and decay pathways. Essential insight on the RNase III mechanism of dsRNA cleavage has been provided by crystallographic studies of the enzyme from the hyperthermophilic bacterium, Aquifex aeolicus. However, those crystals involved complexes containing either cleaved RNA, or a mutant RNase III that is catalytically inactive. In addition, neither the biochemical properties of A. aeolicus (Aa)-RNase III, nor the reactivity epitopes of its cognate substrates are known. The goal of this project is to use Aa-RNase III, for which there is atomic-level structural information, to determine how RNase III recognizes its substrates and selects the target site. I first purified recombinant Aa-RNase III and defined the conditions that support its optimal in vitro catalytic activity. The catalytic activity of purified recombinant Aa-RNase III exhibits a temperature optimum of 70-85°C, a pH optimum of 8.0, and with either Mg2+ or Mn2+ supports efficient catalysis. Cognate substrates for Aa-RNase III were identified and their reactivity epitopes were characterized, including the specific bp sequence elements that determine processing reactivity and selectivity. Small RNA hairpins, based on the double-stranded structures associated with the Aquifex 16S and 23S rRNA precursors, are cleaved in vitro at sites that are consistent with production of the immediate precursors to the mature rRNAs. Third, the role of the dsRBD in scissile bond selection was examined by a mutational analysis of the conserved interactions of RNA binding motif 1 (RBM1) with the substrate proximal box (pb). The individual contributions towards substrate recognition were determined for conserved amino acid side chains in the RBM1. It also was shown that the dsRBD plays key dual roles in both binding energy and selectivity, through RBM1 responsiveness to proximal box bp sequence. The dsRBD is specifically responsive to an antideterminant (AD) bp in pb position 2. The relative structural rigidity of both dsRNA and dsRBD rationalizes the strong effect of an inhibitory bp at pb position 2: disruption of one RBM1 side chain interaction can effectively disrupt the other RBM1 side chain interactions. Finally, a cis-acting model was developed for subunit involvement in substrate recognition by RNase III. Structurally asymmetric mutant heterodimers of Escherichia coli (Ec)-RNase III were constructed, and asymmetric substrates were employed to reveal how RNase III can bind and deliver hairpin substrates to the active site cleft in a pathway that requires specific binding configurations of both enzyme and substrate. / Chemistry

京都大学 / 新制・課程博士 / 博士(工学) / 甲第25304号 / 工博第5263号 / 新制||工||2001(附属図書館) / 京都大学大学院工学研究科分子工学専攻 / (主査)教授 佐藤 啓文, 教授 森 泰生, 教授 跡見 晴幸 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DGAM

La matrice extracellulaire (MEC) intervient dans de nombreux processus biologiques tels que la migration, la différentiation ou l’adhésion cellulaire. Elle est également associée à plusieurs évènements pathologiques. La cohésion de la MEC est assurée par un réseau organisé et complexe de protéines présent au voisinage immédiat des cellules. Ce projet a pour objectif de contribuer à la caractérisation structurale et fonctionnelle de certaines de ces complexes protéiques. Le Gelatin Binding Domain (GBD) (⁶FI¹²FII ⁷⁸⁹FI), localisé dans la région N-terminale de la fibronectine est connu pour interagir avec la transglutaminase 2 (TG2), le collagène de type I, ou encore des protéines d’adhésion bactériennes tel que la FNE (protéine de Streptococcus equi). Mes travaux de thèse portent donc sur la caractérisation fonctionnelle et structurale de ces interactions par des approches biophysiques et biochimiques. Ce travail a permis de cartographier les régions d’interactionentre la TG2 et le GBD d’une part et la FNE et le GBD d’autre part. Nous avons par la suite entrepris une étude par SAXS des complexes TG2/GBD et FNE/GBD et réussi à établir des modèles structuraux d’interaction entre (1) le GBD et le domaine N-terminal de la TG2 et (2) entre la FNE et le sous fragment ⁷⁸⁹FI du GBD. La structure tridimensionnelle de la protéine FNE a été résolue par cristallographie aux rayons X grâce à l’utilisation d’un outil original facilitant l’obtention de cristaux. / The extracellular matrix (ECM) is involved in a number of biological pathways associated with the cell migration, differentiation, adhesion and is also implicated in several pathological events. The cohesion of the ECM is accomplished by a highly organized protein complex network on the cell surface. The Gelatin Binding Domain (GBD) (⁶FI¹²FII ⁷⁸⁹FI) of the N-terminal region of fibronectin is found to interact with the transglutaminase 2 (TG2), collagen type I and the bacterial adhesion protein FNE. In this study, we conducted the structural and functional characterization of the protein complexes involved in the cohesion of ECM. The interactions between either TG2 or FNE and GBD have been characterized and the regions responsible for the interactions have also been mapped. Furthermore, we studied TG2/GBD and FNE/GBD complex by SAXS and built two models underscoring the interactions between (1), the GBD and the Nterminus of TG2 and (2), FNE and the sub-fragment ⁷⁸⁹FI of GBD providing insights on mechanistically elucidating the protein interactions during the cohehsion of ECM. The X-ray structure of the protein FNE of Streptococcus equi has been determined at 1.8 Å, by using an original tool that facilitates obtaining crystals.

No description available.

Doctor of Philosophy / Department of Biochemistry / Subbarat Muthukrishnan / The extracellular matrices of cuticle and peritrophic matrix of insects are composed mainly of chitin complexed with proteins, some of which contain chitin-binding domains. This study is focused on the identification and functional characterization of genes encoding proteins that possess one or more copies of the six-cysteine-containing ChtBD2 domain (Peritrophin A motif =CBM_14 =Pfam 01607) in the red flour beetle, Tribolium castaneum. A bioinformatics search of T. castaneum genome yielded previously characterized chitin metabolic enzymes and several additional proteins. Using phylogenetic analyses, the exon-intron organization of the corresponding genes, domain organization of proteins, and temporal and tissue-specificity of expression patterns, these proteins were classified into three large families. The first family includes 11 proteins essentially made up of 1 to 14 repeats of the peritrophin A domain. Transcripts for these proteins are expressed only in the midgut and only during feeding stages of development. We therefore denote these proteins as “Peritrophic Matrix Proteins” or PMPs. The genes of the second and third families are expressed in cuticle-forming tissues throughout all stages of development but not in the midgut. These two families have been denoted as “Cuticular Proteins Analogous to Peritrophins 3” or CPAP3s and “Cuticular Proteins Analogous to Peritophins 1” or CPAP1s based on the number of ChtBD2 domains that they contain. Unlike other cuticular proteins studied so far, TcCPAP1-C protein is localized predominantly in the exocuticle and could contribute to the unique properties of this cuticular layer. RNA interference (RNAi), which down-regulates transcripts for any targeted gene, results in lethal and/or abnormal phenotypes for some, but not all, of these genes. Phenotypes are often unique and are manifested at different developmental stages, including embryonic, pupal and/or adult stages. The experiments presented in this dissertation reveal that while the vast majority of the CPAP3 genes serve distinct and essential functions affecting survival, molting or normal cuticle development. However, a minority of the CPAP1 and PMP family genes are indispensable for survival under laboratory conditions. Some of the non-essential genes may have functional redundancy or may be needed only under special circumstances such as exposure to stress or pathogens.

Protein engineering and in vitro selection systems are powerful methods to generate binding proteins. In nature, antibodies are the primary affinity proteins and their usefulness has led to a widespread use both in basic and applied research. By means of combinatorial protein engineering and protein library technology, smaller antibody fragments or alternative non-immunoglobulin protein scaffolds can be engineered for various functions based on molecular recognition. In this thesis, a 46 amino acid small albumin-binding domain derived from streptococcal protein G was evaluated as a scaffold for the generation of affinity proteins. Using protein engineering, the albumin binding has been complemented with a new binding interface localized to the opposite surface of this three-helical bundle domain. By using in vitro selection from a combinatorial library, bispecific protein domains with ability to recognize several different target proteins were generated. In paper I, a bispecific albumin-binding domain was selected by phage display and utilized as a purification tag for highly efficient affinity purification of fusion proteins. The results in paper II show how protein engineering, in vitro display and multi-parameter fluorescence-activated cell sorting can be used to accomplish the challenging task of incorporating two high affinity binding-sites, for albumin and tumor necrosis factor-alpha, into this new bispecific protein scaffold. Moreover, the native ability of this domain to bind serum albumin provides a useful characteristic that can be used to extend the plasma half-lives of proteins fused to it or potentially of the domain itself. When combined with a second targeting ability, a new molecular format with potential use in therapeutic applications is provided. The engineered binding proteins generated against the epidermal growth factor receptors 2 and 3 in papers III and IV are aimed in this direction. Over-expression of these receptors is associated with the development and progression of various cancers, and both are well-validated targets for therapy. Small bispecific binding proteins based on the albumin-binding domain could potentially contribute to this field. The new alternative protein scaffold described in this thesis is one of the smallest structured affinity proteins reported. The bispecific nature, with an inherent ability of the same domain to bind to serum albumin, is unique for this scaffold. These non-immunoglobulin binding proteins may provide several advantages as compared to antibodies in several applications, particularly when a small size and an extended half-life are of key importance. / <p>QC 20121122</p>

Spumaretroviren, oder Foamyviren (FV), unterscheiden sich von Orthoretroviren durch mehrere Besonderheiten in ihrer Replikationsstrategie. Das Partikel-assoziierte Hüllglykoprotein (Env-Protein) des „Prototype Foamy Virus“ (PFV) ist im Vergleich zu anderen retroviralen Hüllglykoproteinen einzigartig. Die Koexpression des PFV Env-Proteins für die PFV-Partikelfreisetzung ist essenziell und die spezifische Funktion kann nicht von heterologen viralen Env-Proteinen übernommen werden. Das Env-Protein des PFV durchläuft eine für ein Membranglykoprotein ungewöhnliche Biosynthese. Das Env-Vorläuferprotein besitzt zu Beginn eine Typ-III-Membrantopologie, bei der der N- und der C-Terminus im Zytoplasma lokalisiert sind. Während des Transports zur Zelloberfläche wird es posttranslational durch bisher unbekannte zelluläre Proteasen in mindestens drei Untereinheiten gespalten. Das N-terminale Signalpeptid bzw. Leader-Peptid (LP) hat eine Typ-II-Membrantopologie, mit dem N-Terminus im Zytoplasma und dem C-Terminus im Lumen, wohingegen die Transmembran (TM)-Untereinheit eine Typ-IMembrantopologie besitzt, bei der der N-Terminus im Lumen und der C-Terminus im Zytoplasma lokalisiert sind. Die interne Oberflächen (SU)-Untereinheit assoziiert vermutlich im Lumen mit der extrazellulären Domäne der TM-Untereinheit. Im Rahmen dieser Arbeit wurde der Beweis erbracht, dass Furin oder Furin-ähnliche Proteasen und nicht der Signalpeptidase-Komplex für beide proteolytischen Spaltungen verantwortlich sind. Durch die N-terminale Sequenzierung der SU- und der TM-Untereinheit eines aufgereinigten PFV Env-Immunoadhäsionsproteins wurden N-terminal von beiden Spaltstellen Furin- Konsensussequenzen identifiziert. Mutationsanalysen von zwei sich in diesem Bereich überlappenden minimalen Furin-Konsensussequenzen an der PFV LP/SU-Spaltstelle im wildtypischen PFV Env-Protein bestätigten die Ergebnisse der N-terminalen Sequenzierung und bewiesen, dass nur die erste Spaltstelle genutzt wird. Obwohl diese Mutanten aufgrund geringerer Partikelfreisetzung einen signifikanten Verlust der Infektiosität zeigten, wurde keine Korrelation zur Inhibierung der Spaltung beobachtet, da andere Mutanten mit normaler LP/SU-Spaltung einen ähnlichen Defekt besaßen. Virale Env-Proteine initiieren den Eintritt membranumhüllter Viren in die Wirtszelle durch die Bindung an zelluläre Rezeptoren. Dabei führen Konformationsänderungen in den Env- Proteinen zum Verschmelzen der Virusmembran mit der Zellmembran und weiterhin zur Aufnahme des Kapsids in das Zytoplasma der Wirtszelle. Die foamyviralen Env-Proteine sind in dieser Hinsicht keine Ausnahme und vermitteln die Anheftung an die Wirtszelle durch die Bindung an den bisher unbekannten zellulären Rezeptor. Der zelluläre foamyvirale Rezeptor ist vermutlich ein ubiquitäres Molekül, denn bisher konnte keine Zelllinie identifiziert werden, die gegen FV-Infektionen resistent ist. Bislang existieren nur sehr wenig strukturelle und funktionelle Informationen der extrazellulären Domänen des PFV Env-Proteins. Deshalb wurde im Hauptteil dieser Arbeit die PFV Env-Rezeptorbindungsdomäne (RBD) charakterisiert. Hierfür wurden rekombinante PFV Env-Immunoadhäsionsproteine verwendet und deren Bindungskapazitäten an Zielzellen in der durchflusszytometrischen Analyse bestimmt. Untersuchungen zeigten, dass sowohl die extrazelluläre Domäne der C-terminalen TM-Untereinheit als auch der Transport der Immunoadhäsionsproteine durch das spezifische PFV Env LP zum sekretorischen Weg für die Bindung an Zielzellen entbehrlich sind und ließen vermuten, dass die PFV Env-RBD innerhalb der SU-Untereinheit lokalisiert ist. N- und C-terminale Deletionsanalysen der PFV Env SU-Untereinheit enthüllten eine minimale kontinuierliche RBD von AS 225 bis 555. Interne Deletionen im PFV Env-Protein von AS 397 bis 483 wurden im Gegensatz zu deletierten Regionen von AS 262 bis 300 und AS 342 bis 396 ohne signifikanten Einfluss auf die Wirtszellbindung in Immunoadhäsionsproteinen toleriert. Die Analyse der Immunoadhäsionsproteine mit einzelnen substituierten Cysteinen in der PFV Env SU-Untereinheit zeigten, dass nur die Immunoadhäsionsproteine, die in der nicht essenziellen Region von AS 397 bis 483 lokalisierte Cysteine ersetzt hatten, eine Restbindungskapazität behielten. Interessanterweise zeigte die Analyse von verschiedenen N-Glykosylierungsmutanten eine bedeutende Rolle der Kohlenhydratkette an Position N391 im PFV Env-Protein entweder hinsichtlich der direkten Interaktion mit dem zellulären Rezeptor oder für die korrekte Faltung der PFV Env-RBD. Diese Ergebnisse weisen darauf hin, dass ein diskontinuierliches Sequenzmotiv von AS 225 bis 396 und AS 484 bis 555 für die Bildung der PFV Env-RBD essenziell ist und die darin lokalisierte potenzielle achte N-Glykosylierungsstelle eine entscheidende Rolle bei der Wirtszellbindung spielt. / Spumaretroviruses or foamy viruses (FVs) use a replication pathway with features distinctive from orthoretroviruses. The particle-associated envelope (Env) glycoprotein of prototype foamy virus (PFV) is unique compared to other retroviral envelope proteins since its coexpression is strictly required for the FV particle release process and its function cannot be replaced by heterologous viral glycoproteins. The PFV Env glycoprotein shows a highly unusual biosynthesis. Its precursor protein has a type III membrane topology with both the N-and C-terminus located in the cytoplasm. During its transport to the cell surface, it is posttranslationally processed by yet-unidentified cellular proteases into at least three subunits. The N-terminal signal or leader peptide (LP) has a type II membrane topology, whereas the C-terminal transmembrane (TM) subunit has a type I membrane topology. The internal surface (SU) subunit presumably associates with extracellular domains of TM on the luminal side. Here we provide strong evidence that furin itself or furin-like proteases and not the signal peptidase complex are responsible for both processing events. N-terminal protein sequencing of the SU and TM subunits of purified PFV Env-immunoglobulin immunoadhesin identified furin consensus sequences upstream of both cleavage sites. Mutagenesis analysis of two overlapping minimal furin consensus sequences at the PFV LP/SU cleavage site in the wild-type protein confirmed the sequencing data and demonstrated utilization of only the first site. Although these mutants displayed a significant loss in infectivity as a result of reduced particle release, no correlation to processing inhibition was observed, since another mutant having normal LP/SU processing had a similar defect. Viral Env proteins initiate entry of membrane enveloped viruses into cells by binding to cell surface receptors followed by conformational changes leading to membrane fusion and delivery of the genome containing viral capsid to the cytoplasm. The Env glycoproteins of FVs are no exception and mediate attachment to host cells through binding to an yet unknown ubiquitous cellular receptor molecule because no cell type is currently known that is resistant to FV entry. Little structural and functional information on the extracellular domains of PFV Env is available. In this study we characterized the PFV Env receptor-binding-domain (RBD) by flow-cytometric analysis of recombinant PFV Env immunoadhesin binding to target cells. Analysis showed that the extracellular domains of the C-terminal TM subunit as well as targeting of the recombinant immunoadhesins by the cognate LP to the secretory pathway were dispensable for target cell binding suggesting that the PFV Env RBD is contained within the SU subunit. N- and C- terminal deletion analysis of the SU domain revealed an minimal continuous RBD spanning aa 225-555, however internal deletions covering the region from aa 397-483, but not aa 262-300 or aa 342-396, were tolerated without significant influence on host cell binding. Analysis of individual cysteine point mutants in PFV Env SU revealed that only most of those located in the non-essential region from aa 397-483 retained residual binding activity. Interestingly, analysis of various N-glycosylation site mutants suggests an important role of the carbohydrate chain attached to N391 either for direct interaction with the cellular receptor or for correct folding of the PFV Env RBD. Taken together these results suggest that a bipartite sequence motif spanning aa 225-396 and aa 484-555 is essential for formation of the PFV Env RBD, with N-glycosylation site 8 playing a crucial role for host cell binding.

Combinatorial protein engineering, taking advantage of large libraries of protein variants and powerful selection technology, is a useful strategy for developing affinity proteins for applications in biotechnology and medicine. In this thesis, two small affinity proteins have been subjected to combinatorial protein engineering to improve or redirect the binding. In two of the projects, a three-helix protein domain based on staphylococcal protein A has been used as scaffold to generate so called Affibody molecules capable of binding to key proteins related to two diseases common among elderly people. In the first project, Affibody molecules were selected using phage display technology for binding to Ab-peptides, believed to play a crucial role in Alzheimer’s disease, in that they can oligomerize and contribute to the formation of neural plaques in the brain. The selected Affibody molecules were found to efficiently capture Ab from spiked human plasma when coupled to an affinity resin. The structure of the complex was determined by nuclear magnetic resonance (NMR) and demonstrated that the original helix 1 in the two Affibody molecules was unfolded upon binding, forming intermolecular b-sheets that stabilized the Ab peptide as buried in a tunnel-like cavity. Interestingly, the complex structure also revealed that the Affibody molecules were found to homo-dimerize via a disulfide bridge and bind monomeric Ab-peptide with a 2:1 stoichiometry. Furthermore, Affibody molecule-mediated inhibition of Ab fibrillation in vitro, suggested a potential of selected binders for future therapeutic applications. In the second project, two different selection systems were used to isolate Affibody molecules binding to tumor necrosis factor alpha (TNF), which is involved in inflammatory diseases such as rheumatoid arthritis. Both selection systems, phage display and Gram-positive bacterial display, could successfully generate TNF-binding molecules, with equilibrium dissociation constants (KD) in the picomolar to nanomolar range. Initial characterization of the binding to TNF was evaluated by competitive binding studies between the Affibody molecules and clinically approved TNF antagonists (adaliumumab, infliximab and etanercept) and demonstrated overlapping binding sites with both adaliumumab and etanercept. Furthermore, linkers of different lengths were introduced between Affibody moieties, in dimeric and trimeric constructs that were evaluated for their ability to block the binding between TNF and a recombinant form of its receptor. In the dimeric constructs, a linker length of 20-40 amino acids seemed to have an advantage compared to shorter and longer linkers, and the tested trimeric construct could block the TNF binding at even lower concentration. The results provided valuable information for the design of future Affibody-based molecules that could be investigated in therapeutic or medical imaging applications. In the third project aiming to generate a protein domain with capacity to influence the pharmacokinetics of protein therapeutics, a natural serum albumin-binding domain (ABD) was subjected to an engineering effort aiming at improving the affinity to human serum albumin (HSA), a protein with an exceptional long half-life in serum (19 days). First-generation affinity improved ABD variants were selected using phage display technology from a constructed ABD library. After additional rational engineering of such first generation variants, one variant with a 10,000-fold improved affinity to HSA (KD ≈ 120 fM) was obtained. Furthermore, characterization of this molecule also demonstrated improved affinity to several other serum albumins. When used as a gene fusion partner, this affinity-maturated variant denoted ABD035, should have the potential to extend the half-life of biopharmaceuticals in humans, and several other animal species. / QC 20100722

Four type II toxin-antitoxin (TA) systems were previously identified in Burkholderia pseudomallei K96243. Type II TA toxins are able to induce cell growth arrest or death by interfering with key processes within the organism. BPSS0390-0391 is one of the TA systems previously identified and has homology to hicBA system in Acinetobacter baumannii. B. pseudomallei HicA is able to cause a reduction in the number of culturable cells after expression in E. coli. This study aimed to characterise B. pseudomallei HicA in three ways: by inducing expression of HicA in bacterial species other than E. coli, by identifying amino acids in HicA involved in toxicity and neutralisation by the antitoxin HicB and by examining the interaction of HicA with other TA antitoxins identified within B. pseudomallei genome. A broad host range plasmid encoding BPSS0390 was transformed into a range of Gram negative bacteria including Yersinia pseudotuberculosis IP32953, Vibrio vulnificus E64MW, Salmonella enterica serovar Typhimurium SL1344 and Burkholderia thailandensis E264. Expression of BPSS0390 was toxic in all bacterial species tested, despite the presence of antitoxin BPSS0391 homologues in some species. Unregulated expression in E. coli resulted in the appearance of escape mutants encoding non-toxic variants of HicA. An alanine scanning mutagenesis study of HicA identified 20 mutants where toxicity was abolished despite high levels of expression, but identified no mutants that affected TA complex formation. Finally an existing co-expression assay was modified to examine interactions between HicA and other type II TA antitoxins in B. pseudomallei. The assay revealed no interaction between HicA and non-cognate antitoxins and clarified the role of IPTG as an inhibitor of PBAD promoter on the arabinose operon.